Business Wire
SanMelix Laboratories Wins Stevie® Award in 2021 American Business Awards® for its BEECure™ Line
SanMelix Laboratories
Helping You Heal with Honey
HOLLYWOOD, FL
Health Tech
Helping people live happier, healthier lives through superior natural remedies and distinct treatment components to provide faster and more effective wound and skin care.
$136,960
raised
$1,069,997
previously crowdfunded
124
Investors
$23.8M
Valuation
$1.50
Price per Share
$238.50
Min. Investment
Common
Shares Offered
Equity
Offering Type
$3.93M
Offering Max
0
Days Left
This offering ended on January 12, 2022 and is no longer accepting investments.
Reasons to Invest
First buckwheat honey-based wound dressing patented formulations with anticipated FDA microbial claim for infection control
Our advanced wound care dressings will address the antimicrobial resistance (AR) crisis along with hospital acquired infection (HAI) prevention
Only dressing that has all three mechanisms of wound healing *Anti-microbial claim *Autolytic debridement * Skin regeneration
Overview
Invest in SanMelix
SanMelix is a bioactive skin and wound care company using the natural healing properties of Buckwheat honey, combined with our advanced bioactive enhancements. SanMelix has created products that aid in the healing of acute, chronic, and minor wounds. Our goal is to enhance our market position in the global Skin and Wound Care market.BEECure™ M is not currently available on the market. This product is pending 510(k) submission.
With IP protection on our BEECure™ M dressing and other pending patents, co-created by a renowned Harvard trained podiatric physician, SanMelix's advanced bioactive skin and wound care products can be used in a host of settings and situations. With the CDC investing $300M+ in 59 state & local health departments to detect and prevent resistant threats, our advanced wound care dressings are ideal for HealthCare Associated Infections (HAIs) and the Antimicrobial Resistance (AR) crisis.THE market
The entire population requires wound care
Global skin and wound care market is expected to reach USD $25.98 billion by 2025. 50 million people annually are affected by hard to close wounds worldwide. Chronic wounds affect over 5.7 million patients in the U.S. alone and are estimated to cost $20 billion annually, thus impacting the market growth positively.
- Each year, about 1 in 25 U.S. hospital patients are diagnosed with at least one infection related to hospital care alone; additional infections occur in other healthcare settings. Everyday people require wound care therapies for minor burns, cuts, scrapes, abrasions, and rashes. Of the 3 million patients in the United States receiving radiation 85% experience moderate to severe skin reactions.
THE problem
Human wounds and its burden
Many Healthcare Associated Infections (HAIs) are caused by the most urgent and serious antibiotic-resistant (AR) bacteria and may lead to sepsis or death. Up to one-third of the half billion people with diabetes worldwide will develop a diabetic foot ulcer (DFU). Of these, 17% will require an amputation. There are few effective therapies for radiotherapy, laser therapy and minor thermal burns.
The Solution
Using buckwheat honey products, we can solve them
Our BEECure™ M (buckwheat honey MGO) patented formulation prevents HAI’s by reducing microbial growth to prevent life threatening bacteria (MRSA) from penetrating the dressing while in use.
Case studies using BEECure™ M illustrated accelerated healing and skin regeneration on severe limb threatening wounds.
Our BEECure™ R was developed with buckwheat honey and calming calendula that soothes, hydrates, and revives skin affected by radiation and laser therapy, as well as those exposed to heat and sun.
Our patented advanced wound care (AWC) dressing will be the only product in the market that meets all the requirements of an ideal wound dressing, debridement, tissue repair, and anti-microbial properties.
Products in use
Our BEECure™ skin and wound care products are categorized into two business segments with each being formulated with the common ingredient of buckwheat honey. Our BEECure™ R -Radiation and Laser skin Care cream launched on Amazon in February 2021 and received the Amazon Choice award in the first month. Our advanced wound care products will also be used in hospitals and rehabilitation centers, by physicians through the use of dressings and ointments.
BEECure® M is not currently available on the market. This product is pending 510(k) submission.
how we are different
The difference is in the ingredients
Although manuka honey is the most commonly used honey-based wound treatment on the market, studies have shown that buckwheat honey has superior inherent healing properties when compared to manuka honey due to its higher anti-inflammatory and higher anti-oxidant activities. In addition, SanMelix’ s advanced wound care products have been fortified with antimicrobials to ensure a higher standardized and broader spectrum antibacterial activity. Our patented formulation utilized in our AWC dressings permits SanMelix to launch one of the first bioactive honey dressing to make an antimicrobial claim in the U.S. Our honey dressing is currently undergoing the FDA regulatory 510(k) clearance process. The dressing will prevent biofilms from forming, control wound odor, reduce pain and treatment time while being cost-effective and more environmentally sound.
(source, source, source, source, source, source, source)
OUR TRACTION
Our products have been proven to be safe & effective in early studies
- We reached our crowdfunding goal of $1.07M, and have 1,725 investors on StartEngine
- We launched our BEECure ™ R-radiation and laser skin care on Amazon and Walmart.com
- We have completed testing on our advanced wound care products and will apply for 510(k) pre-market clearance from the FDA in Q3 2021
- We secured a secondary US honey supplier and purchased US manufacturer worldwide formulation rights for BEECure™ R -Radiation and Laser Skin Care which reduces our overall manufacturing cost
- We were granted 2 US patents and 1 Canadian patent and will continue prosecuting our other patent pending formulation application. US trademarks were issued in Q2 2021. Company has also filed an international trademark
Traction by year:
With the funds raised through StartEngine, we plan to complete an evidence-based clinical trial for widespread clinical adoption on our advanced wound care dressing and move to commercialization
why invest
We are here to provide for the growing demand for holistic healing alternatives
There are over 50 million reported cases globally of patients suffering from hard-to-close wounds. 15% of these are diabetic foot ulcers that eventually lead to amputation. With natural Buckwheat Honey, proven to have superior healing and skin care outcomes, at its core, BEECure™ is the only dressing to contain the three essential components of skin and wound care. Antioxidants to boost continuous healing, superior anti-bacterial properties for wound cleansing and heightened resistance against infections, and natural anti-inflammatory and humectant properties to soothe, regenerate and revitalize skin.
We believe we are first to market buckwheat honey skin and wound care products in the United States. Our patented advanced wound care dressing will assist with the complexities of combating Hospital Associated Infections (HAIs) across healthcare settings and in the community.
Our customers will include the VA & DoD, medical supply distributors, physician networks, hospitals, SNFs as well as indirect sales channel for private label/ white label for OTC opportunities. We will market directly to OTC consumers through the world wide web, pharmacies, retails stores, and indirect sales channel for private label/white label. We are capitalizing on a market that has been desperately in need of a natural and safe product that promotes healing and tissue growth while providing infection control. With our current traction and growth, we will continue to innovate new products and work on opening up key distribution regions across the country.
In the Press
The American Business Awards
Product Management & New Product Awards
Health Journal
SanMelix Lab Courts StartEngine Investors with Honey Wound-Care Products
Stock News Now
SanMelix Laboratories, Inc. - Bioactive Wound Care Company Discusses BEECure™, Approval Process, IP Protection and Growth Drivers
CEO CFO
Faster and Healthier Healing
Offering Summary
Company | : | SanMelix Laboratories, Inc. |
Corporate Address | : | 1150 North 35th Avenue Suite 225, HOLLYWOOD, FL 33021 |
Offering Minimum | : | $9,999.00 |
Offering Maximum | : | $3,930,001.50 |
Minimum Investment Amount(per investor) | : | $238.50 |
Terms
Offering Type | : | Equity |
Security Name | : | Class NV Common Stock |
Minimum Number of Shares Offered | : | 6,666 |
Maximum Number of Shares Offered | : | 2,620,001 |
Price per Share | : | $1.50 |
Pre-Money Valuation | : | $23,791,443.00 |
*Maximum Number of Shares Offered subject to adjustment for bonus shares. See Bonus info below.
Investment Incentives and Bonuses*
If you invest $500+, you will receive 3% bonus shares.
If you invest $1,000+, you will receive 5% bonus shares.
If you invest $2,000+, you will receive 10% bonus shares.
If you invest $5,000+, you will receive 15% bonus shares.
If you invest $10,000+, you will receive 20% bonus shares.
All Invested shareholders receive 20% off our Radiation & Laser Skin Care on Amazon. Check Your Email for Discount Code.
*All perks occur when the offering is completed.
The 10% Bonus for StartEngine Shareholders
SanMelix Laboratories Inc. will offer 10% additional bonus shares for all investments that are committed by investors that are eligible for the StartEngine Crowdfunding Inc. OWNer's bonus.
This means eligible StartEngine shareholders will receive a 10% bonus for any shares they purchase in this offering. For example, if you buy 100 shares of Common Stock at $1.50 / share, you will receive and own 110 shares for $150. Fractional shares will not be distributed and share bonuses will be determined by rounding down to the nearest whole share.
This 10% Bonus is only valid during the investors eligibility period. Investors eligible for this bonus will also have priority if they are on a waitlist to invest and the company surpasses its maximum funding goal. They will have the first opportunity to invest should room in the offering become available if prior investments are canceled or fail.
Investors will only receive a single bonus, which will be the highest bonus rate they are eligible for.
Irregular Use of Proceeds
The Company might incur Irregular Use of Proceeds that may include but are not limited to the following over $10,000: Vendor payments.
Show More
Most recent fiscal year-end:
Prior fiscal year-end:
Total Assets
$460,947.00
USD
$237,064.00
USD
Cash And Cash Equivalents
$264,467.00
USD
$51,318.00
USD
Accounts Receivable
$0.00
USD
$0.00
USD
Short Term Debt
$0.00
USD
$0.00
USD
Long Term Debt
$43,334.00
USD
$0.00
USD
Revenues And Sales
$0.00
USD
$0.00
USD
Costs Of Goods Sold
$0.00
USD
$0.00
USD
Taxes Paid
$0.00
USD
$0.00
USD
Net Income
-$404,179.00
USD
-$226,917.00
USD
Risks
A crowdfunding investment involves risk. You should not invest any funds in this offering unless you can afford to lose your entire investment. In making an investment decision, investors must rely on their own examination of the issuer and the terms of the offering, including the merits and risks involved. These securities have not been recommended or approved by any federal or state securities commission or regulatory authority. Furthermore, these authorities have not passed upon the accuracy or adequacy of this document. The U.S. Securities and Exchange Commission does not pass upon the merits of any securities offered or the terms of the offering, nor does it pass upon the accuracy or completeness of any offering document or literature. These securities are offered under an exemption from registration; however, the U.S. Securities and Exchange Commission has not made an independent determination that these securities are exempt from registration.
Updates
Exciting Announcement!
1 day agoHi Everyone,
Steve Weinstein has been appointed to the Board of Directors at SanMelix Laboratories, in Hollywood, Florida. Steve recently retired after a 20-year career with Johnson & Johnson and most recently was the Head of Supply Chain & Operations at Zarbee's, Inc., a leading Health & Wellness company acquired by J&J in September 2018. He is the sixth board member to be appointed to SanMelix, a leader in bioactive advanced wound care dressings and skin care.
At Johnson & Johnson Consumer Companies, Inc., Steve was responsible for collaborating with cross-functional global business partners and regional supply chain partners to ensure that the supply chain network delivered high quality, reliable products at an efficient cost for brands including Johnson’s Baby, Neutrogena, Aveeno and Zarbee’s. Under his direction and leadership over the past 3 years, Zarbee’s Inc. grew an average of 30% annually while saving over $1M annually from revised supply terms with core third-party manufacturers. Mr. Weinstein and his team also reduced supply risk by dual sourcing all key RMs and secured increased capacity of 50-100% on core product forms to meet forecasted growth targets over the next 3-5 years.
As an advisor for SanMelix, Mr. Weinstein will provide guidance regarding joint ventures, product development, manufacturing, distribution, and M&A activities including financing options, to advance the introduction and sales of SanMelix’s products, which focus on the unique medicinal properties of buckwheat honey for wound healing and skin protection. Mr. Weinstein’s 30 years of knowledge and success across supply chain, marketing, innovation and M&A activities in health & beauty, skin health and wellness product global markets along with his contacts and broad-reaching relationships will help accelerate SanMelix’s growth and propel our success. We are delighted to have Steve join our team and assist us in meeting our revenue and business goals. 
Bee Well,
The SanMelix Team.
Gold Recipient!
14 days agoHi Everyone,
SanMelix Laboratories, Inc. is proud to announce that our BEECure® Anti-Itch Lotion has earned the prestigious Mom’s Choice Award® Gold Recipient. Having been rigorously evaluated by a panel of MCA evaluators, BEECure® Anti-Itch Lotion is deemed to be among the best products / services for families.
We are thrilled to earn the Mom’s Choice Awards Honoring Excellence Seal of Approval. We know all the great things the MCA does to connect consumers, educators, and caregivers with the best products and services available for families.
"Our aim to introduce families and educators to best-in-class products and services,” explains Dawn Matheson, Executive Director of the Mom’s Choice Awards. “We have a passion to help families grow emotionally, physically and spiritually. Parents and educators know that products and services bearing our seal of approval are high-quality and also a great value. The MCA evaluation program is designed to incorporate the expertise of scientists, physicians and other specialists; but we also engage parents, children, educators, and caregivers because they are experts in knowing what is best for their families.”
With the evaluation now complete, the testing samples of BEECure® Anti-Itch Lotion will be donated to schools, libraries, hospitals and nonprofit organizations.
Bee Well
Diana
Another Testimonial
17 days agoHi Everyone,
We sent some samples of our BEECure® R to individuals undergoing radiotherapy and one patient posted the following of Instagram.
“I have been using this product a month now. I apply 3 times a day and it looks like it has been helping. Thank you SanMelix for providing a product that help relieve radiation burns.” So thankful to hear our products are helping to heal others.
Bee Well
Diana
Our CEO Entrepreneurial journey
about 1 month agoHi Everyone,
Are you interested in starting your own entrepreneurial journey in skincare but unsure what to expect? Check out Diana's entrepreneurial story here! https://gosolo.subkit.com/sanmelix-laboratories/ . Keep posted for more exciting updates on what's coming soon.
Bee Well
3 Days Left!
about 1 month agoHi Everyone,
Get ready for summer with our anti-itch lotion, after-sun cream, cracked heel relief and other buckwheat honey-based skincare essentials. Only 3 days left, so get yours today!
1-Packs $19.99 NOW $12.50
2-Packs $38.99 NOW $23.00
Shopping Counts as Cardio, Right?
about 1 month ago
Our BIG Sale is going on now thru July 4th . Stock your cabinets and travel bags with ointments that’ll help to provide relief all summer long from sunburns, bug bites, poison ivy and other red, dry, itchy skin concerns.
1-Packs $19.99 NOW $12.50
2-Packs $38.99 NOW $23.00
A Sale SO Good We’ve Extended It!
about 2 months ago
|
Only Hours Left!
about 2 months agoHi Everyone,
It's Dad's day on Sunday. Time to spoil him despite his jokes! The entire BEECure® dark buckwheat honey-based skincare collection is on sale. Sunburns, bug bites, poison ivy or dry, red, itchy skin? It's not too late to send your love. Why Wait....Shop Now!
1-Packs $19.99 NOW $12.50
2-Packs $38.99 NOW $23.00
Did You Miss It?
about 2 months agoHi Everyone,
Did you miss our BIG NEWS FOR FATHER'S DAY?
We’re offering 50% off our entire BEECure line for Amazon Prime Members now through June 22. Share with your friends and family. SHOP NOW!
BEE Well.
50% Off Semi-Annual Sale!
2 months agoHi Everyone,
What better time to purchase the perfect Father’s Day gift. We’re offering 50% off our entire BEECure line for Amazon Prime Members.
For the outdoorsman – BEECure Anti-Itch Cream offers fast-acting relief from bug bites, poison ivy and other skin rashes. Pair that with BEECure After Sun Lotion to provide intensive sunburn relief!
For the indoorsman – Treat Dad to his own skincare cream that’s designed to soothe, nourish and recharge his face, body and feet. #BEECure
SanMelix Community, 
BEE Well
Sincerely, 
{{ profileCtrl.commentsLoading ? 'Loading...' : 'Show More Comments' }}